Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Avricore Health Inc V.AVCR

Alternate Symbol(s):  AVCRF

Avricore Health Inc. is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at advancing pharmacy practice and patient care. The Company is involved in the business of health data and point-of-care technologies (POCT). HealthTab, its flagship offering, is a turnkey point-of-care testing solution that combines point-of-care technologies with a secure, cloud-based platform for tackling pressing global health issues. With just a few drops of blood from a finger prick, the system generates lab-accurate results on the spot and data is reported in real time. The test menu includes up to 23 key biomarkers for screening and managing chronic diseases, such as diabetes and heart disease (e.g., HbA1c, Lipid Profile, eGFR). The HealthTab also has capabilities for bacterial and viral tests, such as strep and COVID-19. The HealthTab platform transforms pharmacies into community point-of-care diagnostic centers.


TSXV:AVCR - Post by User

Bullboard Posts
Post by kingposton Mar 21, 2015 7:34pm
296 Views
Post# 23547742

generics sales ramp very fast and with low selling $...

generics sales ramp very fast and with low selling $...still on the rx comparison, one additional key difference is that generics sales ramp very quickly , w--- once they are taken "on board" by the pharmacy...This is true whether a new generic introduction  or say when one of nphs traditional generics is accepted by a pharmacy..its not following the gradual life cycle sales model of a brand  drug --like rx deals with...  Due to the cost and understood substituability , but a newly introduced generic can get 40% of total market share with in one month of introduction.... and again with very little sales effort , relatively, to the medical community... think about that point..pretty amazing actually... My point being , is that I would not compare to RX thinking that it took RX 4 years to get to 14 million sales..... Generics sales should ramp quick..
Bullboard Posts